MedTrace Logo

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6

NCT00000331 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-05-04

No results posted yet for this study

Summary

The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in healthy, non-drug dependent volunteers.

Conditions

  • Heroin Dependence
  • Opioid-Related Disorders

Interventions

DRUG

Test Drug

DRUG

Placebo Drug

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Leslie Amass, Ph.D. · University of Colorado, Denver

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2002-12-31
Completion
2002-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000331 on ClinicalTrials.gov